Ajovy can start reducing migraine days within the first week of treatment, with some patients noticing improvement as early as day 3. However, the medication reaches its full potential around 6 months, when drug levels stabilize in your body. Here’s what to expect at each stage.
The First Week
Ajovy works faster than many people expect for a preventive medication. In clinical studies, patients experienced a significant reduction in headache hours within the first week of their initial injection. Those who received the higher quarterly dose saw measurable differences by day 3, while the monthly dose group showed significant improvement by day 7.
That first week brought reductions across the board: fewer migraine days, fewer moderate-to-severe headache days, fewer hours spent in pain, and fewer days with nausea, light sensitivity, and sound sensitivity. On average, patients had about one fewer migraine day per month compared to placebo after their first dose. That may sound modest, but for someone tracking 8, 10, or 15 migraine days a month, it’s a meaningful early signal that the medication is working.
The First Three Months
Benefits continue building over the first 12 weeks. In clinical trials spanning that period, roughly 40% of patients on monthly Ajovy achieved at least a 50% reduction in monthly migraine days, compared to 25% on placebo. For people with chronic migraine (15 or more headache days per month), response rates ranged from 38% to 44% depending on the dosing schedule.
If you don’t notice dramatic improvement after your first injection, that’s normal. The drug accumulates gradually, and many patients see their best early results in months two and three as levels build. Three months is generally considered a reasonable window to gauge whether Ajovy is helping you.
Reaching Full Effectiveness at 6 Months
Ajovy reaches steady-state levels in your bloodstream at around 6 months of continuous use. This is the point where the amount of medication entering your system with each dose is balanced by the amount your body clears between doses, creating a consistent therapeutic level. Until that point, each injection nudges your drug levels a little higher, which is why effectiveness can keep improving over several months even though you feel some relief early on.
If you’ve been on Ajovy for 3 months and are seeing partial improvement, it’s worth continuing. The medication may still have room to deliver more benefit as it reaches that steady state.
How Ajovy Prevents Migraines
Ajovy is a lab-made antibody that targets a protein called CGRP, which plays a central role in triggering migraines. During a migraine, CGRP floods the area around your brain’s blood vessels, causing inflammation, dilation, and pain signaling. Ajovy works by binding directly to CGRP molecules in your bloodstream, essentially neutralizing them before they can latch onto receptors and kick off that cascade.
Because Ajovy grabs the CGRP protein itself rather than blocking the receptor it binds to, it’s highly specific. It doesn’t interfere with related proteins that use similar receptors for other functions in your body. This selectivity is part of why the side effect profile is relatively narrow.
Monthly vs. Quarterly Dosing
Ajovy offers two dosing options: one injection every month or three injections given together once every three months. Both schedules produce similar overall results over a 12-week period. The quarterly option predicts roughly the same percentage of responders as the monthly option for both episodic and chronic migraine.
The one difference is speed in the first month. Because the quarterly dose delivers a larger amount of medication upfront, a higher percentage of patients hit the 50% migraine reduction threshold during month one compared to those starting with the smaller monthly dose. By months two and three, the two groups even out. So if faster initial relief matters to you, the quarterly schedule has a slight early advantage, though the long-term benefit is comparable.
What to Expect With Side Effects
The most common side effect is irritation at the injection site, reported by about 43% to 45% of patients in clinical trials (compared to 38% on placebo, so some of that is simply the experience of getting an injection). This typically means temporary redness, pain, or hardness where the needle went in.
Allergic reactions including rash, itching, and hives have been reported, though most were mild to moderate. A small number of patients discontinued treatment or needed additional medication to manage these reactions. Serious allergic responses are rare.
How Long to Give It Before Moving On
Because Ajovy shows measurable effects within the first week and continues improving through month three and beyond, there’s no single cutoff that works for everyone. Most headache specialists recommend evaluating your response after at least three monthly doses. If you’re seeing partial improvement at that point, extending to six months makes sense since the drug hasn’t yet reached its full steady-state level.
Keeping a migraine diary during this period helps you and your doctor spot trends that aren’t obvious day to day. Track not just headache frequency but severity, duration, and how well your acute medications work. Some patients notice their migraines become shorter or less intense before the total number of migraine days drops significantly.